Stiripentol: Unpublished results from the first phase 2 clinical trial in Lennox–Gastaut syndrome conducted in the early 1990s
Open Access
- 23 February 2026
- Vol. 67 (6) , 2845-2854
Abstract
Objective: This study was undertaken to present the results of an exploratory phase 2 trial of stiripentol in Lennox–Gastaut syndrome (LGS). Methods: This exploratory single‐blind, single‐arm, nonrandomized sequential‐period phase 2 study was conducted at four centers in France between January 1989 and August 1993. Eligible patients were aged 2–20 years with LGS and experienced at least one seizure per week despite optimized therapy. After a 1‐month baseline period under a stable treatment regimen, patients received placebo for 1 month followed by stiripentol for 2 months. Results: Sixteen patients with LGS were enrolled, and efficacy was assessable in 14. The median [Q1–Q3] overall seizure frequency decreased from 31 [16–89] at baseline to 14 [8–21] after the first month of stiripentol ( p = .044) and further to 4 [0–18] after the second month ( p = .044). The reduction was consistent across seizure types. Eight patients (57%) were responders (≥50% reduction in overall seizure frequency) at the end of stiripentol treatment, including five (36%) who achieved complete seizure freedom and two with a ≥75% reduction in seizure frequency. All patients reported at least one adverse event during stiripentol treatment, most commonly somnolence, decreased appetite, and vomiting. These effects may be related to the high stiripentol doses administered (median = 91 mg/kg/day in the second month). Despite their frequency, no serious adverse events were reported during the stiripentol treatment period, and no clinically meaningful changes in hematological parameters or liver enzyme levels were observed. Significance: Although this study was conducted before standardized clinical trial designs for LGS were established, a more comprehensive evaluation of stiripentol could have provided further insight into its potential benefits in this severe developmental and epileptic encephalopathy.Keywords
This publication has 27 references indexed in Scilit:
- Efficacy of Stiripentol Beyond Dravet Syndrome: A Retrospective Medical Record Review of Patients with Drug-Resistant EpilepsiesNeurology and Therapy, 2025
- Refining management strategies for Lennox–Gastaut syndrome: Updated algorithms and practical approachesEpilepsia Open, 2024
- Efficacy and safety of stiripentol in the prevention and cessation of status epilepticus: A systematic reviewEpilepsia Open, 2024
- Additional Results from Two Randomized, Placebo-Controlled Trials of Stiripentol in Dravet Syndrome Highlight a Rapid Antiseizure Efficacy with Longer Seizure-Free PeriodsNeurology and Therapy, 2024
- An Update on Stiripentol Mechanisms of Action: A Narrative ReviewAdvances in Therapy, 2024
- Efficacy and tolerability of add‐on stiripentol in real‐world clinical practice: An observational study in Dravet syndrome and non‐Dravet developmental and epileptic encephalopathiesEpilepsia Open, 2023
- Stiripentol in the treatment of adults with focal epilepsy- a retrospective analysisSeizure: European Journal of Epilepsy, 2021
- Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trialThe Lancet Neurology, 2016
- Rufinamide as an adjunctive therapy for Lennox–Gastaut syndrome: A randomized double-blind placebo-controlled trial in JapanEpilepsy Research, 2014
- Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trialThe Lancet, 2000